GD2-CAR-T Cell Therapy for Metastatic Uveal Melanoma – Prof Michael P. Brown

GD2-CAR-T Cell Therapy for Metastatic Uveal Melanoma – Prof Michael P. Brown

Publication date: Jun 06, 2019

Professor Michael P Brown presents on GD2-CAR-T cell therapy for metastatic uveal melanoma at the 1st Australasian Ocular Melanoma Summit, held at the Garvan Institute of Medical Research in Sydney on May 3rd-4th, 2019.

The Australasian Ocular Melanoma Alliance (AOMA) presents the 1st Australasian Ocular Melanoma Summit. The AOMA group was founded in late 2017 by Melanoma and Skin Cancer Trials Ltd to support clinicians and researchers from all disciplines to develop, seek funding for, and collaborate on clinical trials in ocular melanoma.

Follow us at;

Australasian Ocular Melanoma Alliance – @AOMA_MASC

Melanoma and Skin Cancer Trials – @MASC_Trials

For more information contact us at admin@masc.org.au

The event was sponsored/supported by;

Melanoma and Skin Cancer Trials Limited, The Garvan Institute of Medical Research and Kinghorn Cancer Centre, Melanoma Institute Australia, The Save Sight Institute, SydPath and Cancer Australia.

Concepts Keywords
Australia Medicine
Clinical Trials Uveal melanoma
Kinghorn RTT
Melanoma Melanoma
Metastatic Health
Michael Brown Clinical medicine
Ocular Melanoma DecisionDx-UM
Sydney
The Australasian
Uveal Melanoma

Semantics

Type Source Name
disease DOID Cancer
disease MESH Cancer
disease DOID Skin Cancer
disease MESH Skin Cancer
pathway BSID Melanoma
disease DOID Melanoma
disease MESH Melanoma
gene UNIPROT ARID1A
disease DOID Ocular Melanoma
gene UNIPROT WDFY2
disease DOID Uveal Melanoma
disease MESH Uveal Melanoma
gene UNIPROT TRIM13
gene UNIPROT CXADR
gene UNIPROT CASR
gene UNIPROT NR1I3
gene UNIPROT PRKAR1A
gene UNIPROT SPG7

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *